Amedisys, Inc. (AMED - Free Report) is scheduled to report fourth-quarter and 2018 results, after markets close on Feb 27.
In the last reported quarter, the company’s earnings per share surpassed the Zacks Consensus Estimate by 23.4%. Moreover, the company delivered positive surprises in three of the trailing four quarters, the average beat being 16.55%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
We are upbeat about solid contributions from the company’s business lines — Home Health, Hospice and Personal Care. In the third quarter, the company generated around 70.7% of total revenues from Home Health.
Within Home Health, the company is looking to boost same-store volumes via increased admissions and re-certifications. Amedisys also continues to focus on Medicare fee for service growth, which has been increasing sequentially over the last six quarters. PPS (prospective payment system) has also continued to demonstrate strong growth in revenue per episode.
In the third quarter of 2018, total episodic volume growth was 5% and same-store admission growth was 4%. Banking on the company’s quality rating, increased employment of business development staff, analytical means and innovative payment models, the company expects to maintain the growth trajectory in the fourth quarter.
Aduro Biotech (ADRO - Free Report) has an Earnings ESP of +15.23% and a Zacks Rank #2.
Aptose Biosciences (APTO - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>